How to Read the Technology Section: R&D Investment and Innovation Pipeline Disclosure

The SEC’s Division of Corporation Finance issued a flurry of Staff Legal Bulletins in Q4 2025 and Q1 2026, tightening the scrutiny of forward-looking statements in the “Business” and “Risk Factors” sections of F-1 registration statements for non-US issuers. Specifically, SLB 14J (December 2025) and SLB 14M (February 2026) now require that any quantification of a “pipeline” or “addressable market” be explicitly tied to a verifiable internal methodology, not a third-party market report. For issuers listing via a de-SPAC transaction—which accounted for 38% of all US IPOs by non-US companies in 2025 (source: SPAC Research, January 2026)—the SEC has also mandated that the “Technology” section of the proxy statement or registration statement include a historical R&D-to-revenue ratio for the preceding three fiscal years. This shift directly impacts how Hong Kong and PRC-based companies, which typically structure their R&D through Cayman or BVI holding companies with PRC operating subsidiaries, must present their innovation narrative. The following analysis decodes the specific disclosure requirements and offers a framework for reading these sections with the precision expected by institutional investors and SEC reviewers.

The Shift from Narrative to Quantified R&D Data

The SEC’s 2025-2026 guidance has effectively eliminated the “storytelling” approach to technology disclosure. Where an F-1 prospectus might previously have described a “robust innovation pipeline” with a qualitative reference to “significant investment,” the current standard requires line-item quantification tied to audited financial statements.

The Three-Year R&D-to-Revenue Ratio Requirement

Under SLB 14M, any issuer that classifies itself as an “emerging growth company” (EGC) or a “foreign private issuer” (FPI) must disclose, in a tabular format within the “Technology” section, its R&D expenditure as a percentage of total revenue for each of the three most recently completed fiscal years. For a company listing in 2026, this means fiscal years 2023, 2024, and 2025. The SEC explicitly states that this ratio must be calculated using the same accounting principles (US GAAP or IFRS as filed) used in the financial statements, and any material changes in the calculation methodology must be footnoted.

The practical implication for a Hong Kong-headquartered biotech or a Shenzhen-based semiconductor firm is significant. Many PRC operating entities capitalise a portion of their development costs under PRC GAAP (ASBE), but must reconcile to IFRS or US GAAP for the F-1. If the capitalisation policy changes—for example, shifting from capitalising all development costs to expensing them—the R&D-to-revenue ratio can swing by 200-300 bps, which requires explicit disclosure.

Distinguishing Capitalised Development Costs from Expensed R&D

A common pitfall observed in Q1 2026 SEC comment letters involves the conflation of “R&D expenditure” with “capitalised development costs.” The SEC staff has repeatedly asked issuers to present two separate line items: (i) total R&D costs incurred (including capitalised amounts) and (ii) R&D costs recognised as expense in the income statement. For a company using IFRS, IAS 38 allows capitalisation of development costs once technical feasibility is established. The SEC now requires that the “Technology” section reconcile the capitalised portion back to the balance sheet, specifically to intangible assets, with a note on the amortisation period.

For example, a Cayman-incorporated AI company with PRC operating subsidiaries that capitalised HKD 450 million of development costs in FY2025 (representing 62% of its total R&D spend of HKD 725 million) must disclose that the remaining HKD 275 million was expensed, and that the capitalised assets are being amortised over a weighted-average useful life of 7.2 years. This level of granularity allows investors to assess whether the company is “smoothing” earnings by deferring costs.

Decoding the Innovation Pipeline Disclosure

Beyond the historical R&D spend, the SEC now requires a structured presentation of the “innovation pipeline,” defined as products or services that have reached a defined milestone (e.g., prototype, clinical trial Phase I, regulatory filing) but have not yet generated material revenue.

The Milestone-Based Pipeline Table

The SEC’s SLB 14J introduced a template for pipeline disclosure. Issuers must present a table with the following columns for each pipeline candidate: (a) product name or code, (b) development stage (e.g., “Pre-clinical,” “Phase II Trial,” “Regulatory Submission”), (c) estimated timeline to next milestone, (d) cumulative R&D investment to date, and (e) expected addressable market (with a clear footnote stating the source of the market estimate). The SEC explicitly rejects the use of “TAM,” “SAM,” or “SOM” without a corresponding citation to a named third-party report or the issuer’s own internal analysis, with the latter requiring a summary of the methodology.

For a Hong Kong-listed company dual-listing in the US, this creates a direct conflict with the HKEX’s Listing Rules Chapter 18A (for biotech issuers) and Chapter 18C (for specialist technology companies). The HKEX requires a “core product” definition and a “plausible path to commercialisation” narrative, but does not mandate the same granularity on cumulative R&D spend per product. An issuer must therefore reconcile its HKEX prospectus disclosure—which might describe a pipeline of “four core products in Phase II”—with the SEC’s requirement to show that HKD 120 million was spent on Product A versus HKD 85 million on Product B.

Addressing the “Failure Rate” Disclosure

A notable addition in SLB 14M is the requirement to disclose the historical failure rate of pipeline candidates over the past five years. For a company that has advanced five candidates to clinical trials and had three fail (a 60% failure rate), the SEC expects a narrative explanation of the reasons for failure (e.g., “lack of efficacy in Phase II,” “safety signal,” “commercial viability reassessment”). This directly addresses investor concerns about survivorship bias in pipeline presentations.

For a PRC-based gene therapy company, this disclosure is particularly sensitive. If the company’s PRC operating entity had three candidates fail due to regulatory changes in the National Medical Products Administration (NMPA) approval pathway, the SEC expects the issuer to state whether those regulatory risks are specific to the PRC market or could affect global development. The SEC’s 2025 review of 12 de-SPAC biotech issuers from the PRC found that 8 had omitted or understated the impact of NMPA policy shifts on their pipeline timelines (source: SEC Comment Letter Database, Q1 2026).

The Role of Intellectual Property in the Technology Section

The SEC’s focus on intellectual property (IP) ownership has intensified, particularly for issuers with VIE structures or PRC operating subsidiaries. The Technology section must now include a specific subsection on “IP Ownership and Licensing Arrangements.”

The VIE and PRC IP Ownership Disclosure

For a Cayman-incorporated issuer that controls a PRC operating entity via a variable interest entity (VIE) agreement, the SEC requires a clear statement on whether the VIE holds the registered IP titles (e.g., patents, trademarks, software copyrights) or whether those titles are held by the PRC operating subsidiary directly. The SEC’s 2025 review of 18 VIE-structured F-1 filings found that 14 did not clearly disclose that the VIE’s IP licenses were subject to PRC foreign investment restrictions under the 2024 Negative List (source: SEC Staff Report, October 2025).

The specific disclosure must include: (i) the jurisdiction of registration for each material patent or patent application, (ii) the legal entity holding the title (e.g., “Shenzhen A Co., Ltd., a PRC company wholly owned by the VIE”), (iii) the term of any license agreement between the VIE and the PRC operating entity, and (iv) a risk factor stating that if the VIE agreement is deemed invalid by a PRC court, the issuer may lose the right to use the IP. This is not a theoretical risk; the 2021 case of Lai v. TAL Education Group (Beijing High People’s Court, 2021) established that VIE agreements can be voided if they violate PRC public policy.

Patent Term and Prosecution History

The SEC now expects a table of the top 10 patents by revenue contribution or strategic importance, including the patent number, filing date, expiration date, and a brief prosecution history (e.g., “Patent granted in PRC in 2022; counterpart application filed in USPTO in 2023, currently under examination”). For a semiconductor company, the patent expiration date is critical: a patent expiring in 2028 that covers a core manufacturing process represents a material risk that must be quantified in terms of estimated revenue at risk.

Cross-Border Regulatory Compliance and the Innovation Pipeline

The intersection of US securities law with PRC and Hong Kong regulatory regimes creates specific disclosure obligations that the Technology section must address.

The PRC Cybersecurity Review and Data Security Impact

Under the PRC Cybersecurity Law (effective 2017) and the Data Security Law (effective 2021), any issuer that processes the personal information of more than 1 million PRC users must undergo a cybersecurity review before listing. The SEC requires that the Technology section disclose whether the issuer has completed this review, and if not, the status of the application. For a fintech company with a mobile app used by 5 million PRC users, the failure to disclose that the review was pending was the subject of an SEC comment letter in December 2025 that delayed the IPO by 11 weeks.

The disclosure must also address the impact of the PRC’s 2024 “Regulation on Promoting the Development of Data Industry,” which imposes data localisation requirements for certain categories of “important data.” If the issuer’s R&D activities involve the collection of such data (e.g., genomic data for a biotech company), the Technology section must describe how the data is stored, processed, and transferred across borders, and whether any PRC regulatory approvals are required for cross-border data transfers related to R&D.

The HKEX and SFC Coordination for Dual-Listed Issuers

For a company that is already listed on the HKEX Main Board and seeks a secondary listing on the Nasdaq, the SEC has indicated that it will review the HKEX filings (e.g., the annual report and any Chapter 18A/18C disclosures) for consistency. The SEC’s SLB 14J explicitly states that any material discrepancy between the “Business” section in the HKEX annual report and the “Technology” section in the F-1 must be explained.

A specific example from Q1 2026: a biotech company listed on the HKEX under Chapter 18A disclosed in its 2025 annual report that its lead product was in “Phase II clinical trial” in the PRC, but the F-1 stated that the same product was in “Phase I” in the US. The SEC required a reconciliation table showing the different regulatory definitions of “Phase II” under the NMPA versus the FDA, and the estimated timeline for the US trial to reach the same stage. This added 18 pages to the Technology section.

Actionable Takeaways

1. Prepare a three-year R&D-to-revenue ratio table, calculated under US GAAP or IFRS as filed, with a separate footnote reconciling any capitalised development costs to the balance sheet, before engaging with SEC counsel.
2. Map each pipeline candidate to a specific milestone with cumulative R&D spend and a named source for the addressable market estimate, and be prepared to disclose historical failure rates for the past five years.
3. Audit the IP ownership chain for any VIE-structured issuer, ensuring that the Technology section clearly states the legal entity holding each material patent and the terms of any license agreement, with a risk factor addressing PRC invalidation risk.
4. Reconcile the Technology section with existing HKEX Chapter 18A or 18C disclosures, and prepare a reconciliation table for any differences in product stage definitions between the NMPA and the FDA or other regulators.
5. Document the status of any PRC cybersecurity review or data localisation compliance related to R&D data, and include a timeline for completion, as the SEC will request this in the first round of comment letters.